EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Growing concerns about using hypoxia-inducible factor prolyl hydroxylase inhibitors for the treatment of renal anemia

Takeshi Nakanishi, Takahiro Kuragano

Clinical Kidney Journal · 01.03.2024 · 17 (3)

DOI: 10.1093/ckj/sfae051 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Kidney Journal, online erschienen am 28.02.2024. Verfasst von Takeshi Nakanishi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Kidney, Dialysis and Cardiology, Department of Internal Medicine, Hyogo Medical University, Nishinomiya, Hyogo, Japan. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) have emerged as a novel therapeutic class for treating anemia in patients with chronic kidney disease. Small molecule analogs of α-ketoglutarate (AKG), an essential substrate for 2-oxoglutarate-dependent dioxygenases (2-OGDDs), including prolyl hydroxylase domain proteins (PHDs), inhibit PHDs pharmacologically and thereby prevent HIF degradation. HIF stabilization alleviates anemia through several stimulatory effects on erythropoiesis, but it also affects the expression of many anemia-unrelated genes whose protein products exert important functions in vivo. Therefore, the pleiotropic effects of HIF stabilization under normoxic conditions deserve to be examined in more detail. Specifically, we believe that particular attention should be given to epigenetic modifications among the various AKG-based metabolic systems that may be altered by HIF-PHIs. It is noteworthy that AKG has been reported to exert health-protective actions. AKG-based metabolic systems include enzymes associated with the tricarboxylic acid cycle and amino acid metabolism, as well as 2-OGDD-mediated processes, which play important roles in many biological reactions. In this review, we examine the multifaceted effects of HIF-PHIs, encompassing not only their on-target effect of HIF stabilization but also their off-target inhibitory effects on various AKG-based metabolic systems. Furthermore, we examine its potential relevance to cardiovascular complications, based on clinical and animal studies suggesting its involvement in vascular calcification, thrombogenesis and heart failure. In conclusion, although HIF-PHIs offer a promising avenue for anemia treatment in CKD patients, their broader impact on multiple biological systems raises substantial concerns. The intricate interplay between HIF stabilization, AKG competition and cardiovascular complications warrants extensive, long-term investigations to ensure the safety and usefulness of HIF-PHIs in clinical practice.

Schlagwörter

Stichwörter der Autor:innen

2-oxoglutarate-dependent dioxygenasesHIF-PHIsepigeneticsrenal anemiaα-ketoglutarate

Autor:innen und Institutionen

  • Division of Kidney, Dialysis and Cardiology, Department of Internal Medicine, Hyogo Medical University, Nishinomiya, Hyogo, Japan.
  • Department of Nephrology, Gojinkai Sumiyoshigawa Hospital, Kobe, Hyogo, Japan.

Zitieren

APA

Nakanishi, T., & Kuragano, T. (2024). Growing concerns about using hypoxia-inducible factor prolyl hydroxylase inhibitors for the treatment of renal anemia. Clinical Kidney Journal, 17(3). https://doi.org/10.1093/ckj/sfae051

Vancouver

Nakanishi T, Kuragano T. Growing concerns about using hypoxia-inducible factor prolyl hydroxylase inhibitors for the treatment of renal anemia. Clinical Kidney Journal. 2024;17(3). doi:10.1093/ckj/sfae051

BibTeX
@article{Nakanishi2024,
  author = {Nakanishi, Takeshi and Kuragano, Takahiro},
  title = {Growing concerns about using hypoxia-inducible factor prolyl hydroxylase inhibitors for the treatment of renal anemia},
  journal = {Clinical Kidney Journal},
  year = {2024},
  volume = {17},
  number = {3},
  doi = {10.1093/ckj/sfae051}
}
Kostenlos starten →